• DOI:10.1016/j.mce.2003.10.008
Corpus ID: 19701784

The 45-year story of the development of an anti-aldosterone more specific than spironolactone

@article{Mnard2004The4S,
  title={The 45-year story of the development of an anti-aldosterone more specific than spironolactone},
  author={J. M{\'e}nard},
  journal={Molecular and Cellular Endocrinology},
  year={2004},
  volume={217},
  pages={45-52}
}

• J. Ménard
• Published 2004
• Medicine
• Molecular and Cellular Endocrinology

At the early stage of its development in 1957, the daily dose of spironolactone necessary to improve various pathological conditions was not precisely determined and dose-dependent sexual side effects limited its long-term use. Prescription of high daily doses and absence of selectivity for the mineralocorticoid receptor explain these limitations. The 9-11alpha epoxy group added to mexrenone by the Ciba-Geigy chemists in 1984 and improved chemical synthesis at Searle, permitted the original… Expand